ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
INmune Bio Inc

INmune Bio Inc (INMB)

1.70
0.02
(1.19%)
Closed July 03 3:00PM
1.66
-0.04
(-2.35%)
After Hours: 6:55PM

INmune Bio Inc (INMB) Options

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.000.000.000.700.700.000.00 %01-
2.000.000.000.080.080.000.00 %01,300-
3.000.000.000.050.050.000.00 %050-
4.000.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.000.000.000.150.150.000.00 %01-
2.000.000.000.400.400.000.00 %031-
3.000.000.000.000.000.000.00 %00-
4.000.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LIMENeutron Holdings Inc
US$ 25.10
(1,430.49%)
1.12M
CLROClearOne Inc
US$ 6.4788
(101.20%)
88.54M
CWDCaliberCos Inc
US$ 1.21
(87.51%)
338.03M
MIDDVMiddleby Corporation
US$ 139.52
(72.23%)
1.54k
DSYBig Tree Cloud Holdings Limited
US$ 4.44
(54.17%)
22.72M
TCToken Cat Ltd
US$ 2.9699
(-38.13%)
1.66M
LHAILinkhome Holdings Inc
US$ 1.7252
(-37.04%)
20.13M
ELTXElicio Therapeutics Inc
US$ 3.26
(-36.58%)
4.35M
NCRANocera Inc
US$ 0.0647
(-35.69%)
10.63M
JLHLJulong Holding Limited
US$ 7.33
(-33.90%)
150.01k
LIMNLiminatus Pharma Inc
US$ 0.1365
(18.90%)
525.18M
CWDCaliberCos Inc
US$ 1.21
(87.51%)
338.03M
INLFINLIF Limited
US$ 0.022
(-32.93%)
219.73M
SURGSurgePays Inc
US$ 0.578
(39.31%)
178.02M
NVDANVIDIA Corporation
US$ 194.83
(-1.39%)
143.34M

INMB Discussion

View Posts
81vette 81vette 1 week ago
https://investorshub.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/98808296/inmune-bio-inc-achieves-mhra-approval-of-pip-for
👍️0
81vette 81vette 1 week ago
https://investorshub.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/trades
👍️0
jondoeuk jondoeuk 6 months ago
It failed in the first trial https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171636087 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174142836

It failed in the second trial https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175902173 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176527055

They now talk about a phase two expansion trial in solid tumours with residual disease.
👍️0
AKsuited AKsuited 7 months ago
Wen $10? 
GL here
👍️0
tw0122 tw0122 7 months ago
2.35
👍 1
jondoeuk jondoeuk 11 months ago
From the wording of the press release, it seems there was (at least some) activity, but not enough to translate into any CRs or PRs https://finance.yahoo.com/news/inmune-bio-care-pc-trial-120000411.html
👍️0
jondoeuk jondoeuk 1 year ago
The trial missed its primary endpoint. The trial also missed its secondary endpoints. I doubt they will find a partner to advance it.
👍️0
tredenwater2 tredenwater2 1 year ago
Perhaps INMB wojld have benefitted from using the FDA’s open label adaptive ph 2 cross over trial like Anavex did. We are clearly on a firm foundation of efficacy because if the ph 2a as we near approval in the EU.

On a financing note, yes I also highly appreciate Dr. Missling’s clear savvy moves to minimally allow dilution to Anavex shareholders on the way to approval…..inhouse!

Management of INMB should be ashamed for securing a financing deal ahead of releasing bad news. Did the funding source know the data and shorted against the box? Smells very bad!
👍️ 2
tschussmann1 tschussmann1 1 year ago
Every Alzheimer's trial fail makes me appreciate AVXL that much more...
👍️ 2
tschussmann1 tschussmann1 1 year ago
Yes indeed! Fortunately it was a small stake...not much effect on the portfolio.
👍️0
retireat40 retireat40 1 year ago
Looks like a terrible decision 
👍️0
tschussmann1 tschussmann1 1 year ago
The low 5's after the 20% share increase priced at 6.30 provided a nice entry point...and not long to wait to see it it was a good decision.
👍️ 2
murocman murocman 1 year ago
Happens all the time.  Not a surprise.
👍️0
retireat40 retireat40 1 year ago
$5's
👍️0
retireat40 retireat40 1 year ago
Then they dropped an offering at $6.30. What a shit move. 
👍️0
rbl100 rbl100 1 year ago
OFFERING - @ $6.30 per share.....
👍️0
tw0122 tw0122 1 year ago
$13s 
👍️0
GhosTraderX GhosTraderX 1 year ago
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
https://ih.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/96320079/inmune-bio-inc-to-announce-top-line-results-from
GhosT
👍️ 6
jondoeuk jondoeuk 1 year ago
An update https://www.globenewswire.com/news-release/2025/06/02/3091859/0/en/Syncromune-Inc-Presents-Positive-Results-from-SYNC-T-Therapy-SV-102-Phase-1-Metastatic-Prostate-Cancer-Trial-at-ASCO-2025.html

https://www.globenewswire.com/news-release/2025/05/30/3091053/0/en/Syncromune-Announces-First-Patient-Dosed-in-LEGION-100-Phase-2a-Trial-of-SYNC-T-Therapy-SV-102-for-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer.html
👍️0
jondoeuk jondoeuk 1 year ago
Apples to oranges, but this is the kind of data you want to see https://syncromune.com/wp-content/uploads/2024/04/SYNC-T-AACR-Website.pdf
👍️0
jondoeuk jondoeuk 1 year ago
So no scans, waterfall or swimmer plots! Doesn't look like there is any single-agent activity https://archive.fast-edgar.com/20250304/AD29K22CLM22K282222G22Y2M9BIZ2224272/ea023314201ex99-1_inmune.htm

Drugs with no single-agent activity rarely, if ever improve outcomes in randomised and controlled trials when used alone or in combination.
👍️0
MartinLutherKing MartinLutherKing 2 years ago
ELAB Partnership
👍️0
Monksdream Monksdream 2 years ago
INMB under $5
👍️0
Monksdream Monksdream 2 years ago
INMB new 52 week low
👍️0
tw0122 tw0122 2 years ago
Study Demonstrate XPro converts microglia from a demyelinating cell to a remyelinating cell.Multi-year study published has implications for many CNS diseases including Alzheimer's.
👍️0
tw0122 tw0122 2 years ago
INMB 5.27 something brewing over here in some
👍️0
Monksdream Monksdream 2 years ago
INMB new 52 week low
👍️0
Monksdream Monksdream 2 years ago
INMB under $10
👍️0
jondoeuk jondoeuk 2 years ago
''The third patient for the INKmune™ AML program in UK and EU has been enrolled and subsequent to their completion of follow-up, the company will wind down the AML program to focus resources on the prostate-cancer program and other solid tumors.'' https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html

Good luck to them in solid tumours!
👍️0
Monksdream Monksdream 2 years ago
INMB indeed it did
👍️0
DollarDan DollarDan 3 years ago
Starting to move up!
👍️0
jondoeuk jondoeuk 3 years ago
Did the trial in ovarian ever start?
👍️0
derkampfer derkampfer 3 years ago
Don't need to convince us. We are fully invested and believers in both the INKmune NK cell therapy for certain cancers as well as XPro for AD and possibly others neuro inflammation sensitive diseases, including Parkinson’s.

Two robust programs and each have multi-billion value potential based on TAM

Exciting times.

GLTA longs
👍️0
jondoeuk jondoeuk 3 years ago
Sure, it is early days in patients, but the data has yet to be https://ashpublications.org/blood/article/140/Supplement%201/4590/492304/In-Vivo-Generation-of-Memory-like-NK-Cells-for-the

Keep in mind that the ORR (focusing on R/R AML) is ~30-35% across multiple trials using adoptive transfer of non-engineered NK cells.
👍️0
dennisdave dennisdave 4 years ago
blocked
👍️0
conix conix 4 years ago
INMB chart....finally a reversal?

👍️0
conix conix 5 years ago
INMB Chart

👍️0
derkampfer derkampfer 5 years ago
XPro news also impressive. Data very.

“The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio
👍️0
derkampfer derkampfer 5 years ago
INKmune news was impressive. Albeit one patient dosed additional eight (8) in line. No toxicity. Ovarian cancer on deck.

https://finance.yahoo.com/news/inmune-bio-inc-announces-biomarker-200000970.html
👍️0
spartex spartex 5 years ago
Almost, $13 to $10 is a downward slope. but maybe over time things will be reversed??
👍️0
spartex spartex 5 years ago
Booooooom? More like, BurP! LOL. Still researching INMB
👍️0
derkampfer derkampfer 5 years ago
New run began today. Deeper dive Alzheimer’s drug they’re developing is phenomenal. Early studies some patients seeing reversed effects.

Unbelievable.
👍️0
Fress Fress 5 years ago
$INMB just ran from $2.00 to 30.00 congrats to the longs. what a beast of a stock.



*INmune Bio shares are trading higher after the company announced results for its Phase 1B study of XPro1595. The results show a decrease in biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid and MRI.



$PDSB CD8+ (killer) T-cells. T cell platform is next.


$INMB
👍️0
john sezso john sezso 5 years ago
I need a bigger rake to scoop up all this cash trade....
👍️0
john sezso john sezso 5 years ago
Still crickets here....
👍️0
john sezso john sezso 6 years ago
Good enough for Harry Reid it's good enough for me. I'm in for the 50's
👍️0
byrdiesoccer byrdiesoccer 6 years ago
They are speaking with Roth Capital right now
👍️0
akamaii akamaii 6 years ago
Shorts bring this to 8 I wanna buy
👍️0
l2 hunter l2 hunter 6 years ago
INMB CHART >>>> going in position before test $25 next days again. after $25 blue skies... $13-$15 range a gift imho think will run big next days

👍️0
starkd748 starkd748 6 years ago
Wow that public offering is peanuts ...Kaboom here tomorrow
👍️0